Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 42 Small Cell Lung Carcinoma 19 Breast Neoplasms 16 Sarcoma 12 Lung Neoplasms 9 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Hepatocellular 7 Thyroid Neoplasms 6 Stomach Neoplasms 6 Nasopharyngeal Carcinoma 6 Esophageal Neoplasms 6 Ovarian Neoplasms 5 NSCLC 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pheochromocytoma 4 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Neoplasms 3 Glioma 3 Cholangiocarcinoma 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Platinum-resistant Ovarian Cancer 2

Interventions

Capecitabine 6 Irinotecan 5 Fluorouracil 5 Cisplatin 5 Oxaliplatin 4 Leucovorin 4 Gemcitabine 4 apatinib 3 Sorafenib 3 Bevacizumab 3 tislelizumab 2 pembrolizumab 2 Sunitinib 2 Radiotherapy 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Cyclophosphamide 2 Cetuximab 2 Aspirin 2 Ascorbic Acid 2 130-nm albumin-bound paclitaxel 2 spartalizumab 1 sintilimab 1 regorafenib 1 pyrotinib 1 pemigatinib 1 lutetium Lu 177 dotatate 1 huachansu 1 halofantrine 1 guadecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Digestive System Neoplasms × anlotinib × Clear all

NCT05262335 2023-11-28

ALTER-G-001

Ruijin Hospital

Phase 2 Unknown

Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡